Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Shares Outstanding (Diluted Average) (2021 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 27.67% year-over-year to $3.2 million; the TTM value through Sep 2025 reached $3.2 million, up 27.67%, while the annual FY2024 figure was $2.5 million, 7.7% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $3.2 million in Q3 2025 for Cyclerion Therapeutics, up from $3.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $39.1 million in Q4 2021 and bottomed at $43425.0 in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $8.1 million, with a median of $2.5 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Diluted Average) plummeted 94.45% in 2022 and then skyrocketed 4910.94% in 2023.
  • Cyclerion Therapeutics' Shares Outstanding (Diluted Average) stood at $39.1 million in 2021, then tumbled by 94.45% to $2.2 million in 2022, then rose by 7.59% to $2.3 million in 2023, then rose by 7.7% to $2.5 million in 2024, then grew by 28.08% to $3.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $3.2 million, $3.1 million, and $2.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.